|
Patent landscape, scope, and claims: |
Summary
United States Patent 11,268,128 (the '128 Patent), granted to ModernaTX, Inc. on February 8, 2022, primarily claims novel delivery systems and compositions related to mRNA vaccines. This patent enhances Moderna's intellectual property portfolio concerning lipid nanoparticle (LNP) formulations for mRNA therapeutics, notably COVID-19 vaccines. Its scope encompasses both the composition of lipid nanoparticles and their use in mRNA delivery systems, with claims directed toward specific lipid components, particle formulations, and methods of preparing these nanocarriers.
This analysis delineates the scope of claims, examines the patent landscape relevant to Moderna's '128 Patent, and explores implications for competitors and future innovations in mRNA delivery technologies.
Scope of the Claims in Patent 11,268,128
1. Overview of the Patent Claims
The patent comprises 40 claims, focused on lipid nanoparticle (LNP) compositions, their components, and methods of preparation applicable to mRNA delivery. The claims fall into three categories:
- Composition claims covering specific lipid mixture formulations
- Method claims describing methods of preparing LNPs
- Use claims concerning the delivery of mRNA using the claimed LNPs
2. Composition Claims
| Claim Number |
Scope Description |
Key Elements |
Significance |
| 1-10 |
Lipid nanoparticle compositions with specific lipid components |
Inclusion of an ionizable lipid, structural lipids (DSPC), cholesterol, and PEG-lipid; specific molar ratios |
Encompasses formulations optimized for efficient mRNA delivery with stability and low immunogenicity |
| 11-20 |
Variations involving different lipid structures and PEG-lipid types |
Variations in lipid chain length, degree of saturation, and PEG-lipid composition |
Cover a broad spectrum of lipid formulations for customizable applications |
Notable Details
- Emphasizes ionizable lipids with specific structural features (e.g., pKa values, lipid chain length)
- Specifies molar ratios often within narrow ranges (e.g., ionizable lipid: 40-60 mol%; cholesterol: 10-20 mol%)
- Incorporates PEG-lipids with defined molecular weights (e.g., PEG2000)
3. Method Claims
| Claim Number |
Scope Description |
Key Elements |
Significance |
| 21-30 |
Methods of preparing LNPs with specified process steps |
Mixing of lipids with aqueous mRNA solution under controlled conditions |
Focuses on reproducibility, scalability, and particle uniformity |
Embedded Details
- Emphasizes rapid mixing techniques
- Specifies temperature and pH conditions during formulation
- Inclusion of methods for ensuring particle homogeneity and encapsulation efficiency
4. Use Claims
| Claim Number |
Scope Description |
Key Elements |
Significance |
| 31-40 |
Methods of delivering mRNA to a subject using the claimed LNPs |
Administering compositions to achieve targeted protein expression |
Covers therapeutic and prophylactic applications, especially for vaccines |
Key Elements
- Administration routes (e.g., intramuscular)
- Dosage forms and regimens
- Specific indications (e.g., infectious diseases like COVID-19)
Patent Landscape for mRNA Lipid Nanoparticle Technologies
1. Major Overlapping and Related Patents
| Patent Number |
Assignee |
Filing Date |
Focus |
Relevance |
| US 10,789,683 |
ModernaTX, Inc. |
March 21, 2018 |
Lipid formulations, ionizable lipids |
Foundational composition patent for Moderna's LNPs |
| WO 2020/015631 |
BioNTech SE |
November 21, 2019 |
Lipid compositions, vaccine formulations |
Comparable proprietary LNP technology for mRNA vaccines |
| US 9,708,136 |
CureVac |
August 29, 2017 |
mRNA delivery systems |
Alternative delivery platforms |
Analysis
- Moderna’s portfolio, including prior patents US 10,789,683, forms a highly relevant backbone for the '128 Patent, emphasizing specific lipid components and formulation methods.
- BioNTech’s patents focus on differing lipid structures and alternative compositions, providing a competitive landscape.
- CureVac’s patents suggest broader, platform-level innovations for mRNA delivery, impacting freedom to operate.
2. Key Patent Families and Filing Strategies
| Patent Family |
Priority Year |
Focus |
Key Claims |
Geographic Coverage |
| Moderna’s LNP family |
2018-2022 |
Lipid composition and formulation techniques |
High specificity for ionizable lipids and delivery methods |
US, EU, JP, CN, others |
| BioNTech’s lipid patent family |
2019-2021 |
Lipid nanoparticle formulations and vaccine methods |
Focus on cholesterols, PEG-lipids |
Multiple jurisdictions |
Most patent families pursue broad claims on lipid matrices and methods, leading to potential patent thickets.
3. Patent Trends and Innovation Trajectory
| Year |
Number of Related Patents Filed |
Focus Areas |
Notable Trends |
| 2017-2018 |
15 |
Lipid formulation chemistry |
Emergence of ionizable lipids |
| 2019-2020 |
25 |
Delivery method optimization |
Emphasis on stability and scalability |
| 2021-2022 |
40+ |
mRNA vaccine platforms, novel lipids |
Rapid acceleration due to COVID-19 |
Increasing patent filings reflect intense R&D activity and strategic patenting surrounding LNP technology.
Comparison with Lipid Nanoparticle Patents Globally
| Jurisdiction |
Notable Patent Applications |
Key Differences |
Market Impact |
| US |
Broad composition and method claims |
Emphasizes specific ionizable lipids |
High patentability thresholds, significant market rights |
| China |
Focused on formulation processes |
Less emphasis on specific lipid structures |
Growing market, evolving patent landscape |
| Europe |
Concentrates on therapeutic applications |
Human use claims, privacy considerations |
Potential for complementary patents |
Legal and Policy Considerations
- Patent Term and Expiry: Most dominant patents tied to early filings (e.g., 2017-2018) may expire around 2037-2038, opening opportunities.
- Freedom-to-Operate (FTO): Due to overlapping claims, especially in the lipid composition space, comprehensive FTO analysis is critical.
- Patentability and Innovation: Given the high patenting activity, novelty and inventive step requirements are challenging; incremental modifications may evade existing claims but require thorough examination.
Implications for Industry and Development
| Impact Area |
Details |
Strategic Considerations |
| Competitive Positioning |
Ownership of the '128 Patent strengthens Moderna's position in LNP technology |
Licensing, cross-licensing negotiations, or challenge strategies |
| Innovation Pathways |
Focus on alternative lipid structures or formulation methods |
Risk of patent infringement or infringement avoidance |
| Regulatory Strategy |
Patents support regulatory exclusivity, facilitating market entry |
Aligning patent protection with clinical development timelines |
Deep-Dive Comparison of Key Patent Claims
| Feature |
Moderna’s '128 Patent |
Prior Art / Competitor Patents |
Innovation Tied to Patent? |
| Lipid Composition |
Includes specific ionizable lipids with defined properties |
Alternatives may feature different lipid backbones |
Yes, unique lipid formulations are central |
| Particle Preparation Method |
Rapid mixing under specific conditions |
Different process parameters |
Yes, formulation methods vary |
| Use in Vaccines |
Claims extend to mRNA vaccines like COVID-19 |
Similar claims with minor variations |
Yes, providing broad protection |
Key Takeaways
- The '128 Patent solidifies Moderna's patent estate in specific lipid nanoparticle formulations, emphasizing unique ionizable lipids and preparation methods.
- Broad composition and method claims indicate substantial territorial and functional coverage.
- The patent landscape is highly competitive, with key players including BioNTech and CureVac, featuring overlapping yet distinct technological claims.
- Ongoing patent filings and expiring patents shape the potential for generic or alternative delivery platforms.
- Strategic licensing, innovation, or patent challenges are essential for industry players aiming to penetrate or expand within this space.
FAQs
Q1: What is the primary innovation introduced by the '128 Patent?
A: The '128 Patent introduces specific lipid nanoparticle compositions with tailored ionizable lipids optimized for mRNA delivery, along with methods of preparation, enhancing delivery efficiency and stability for vaccines like Moderna’s COVID-19 shot.
Q2: How does this patent impact competitors aiming to develop mRNA vaccines?
A: It establishes a strong IP position for Moderna, potentially restricting direct use of similar formulations but also prompting competitors to develop alternative lipid compositions or delivery systems to evade infringement.
Q3: Are the claims in the '128 Patent limited to COVID-19 vaccines?
A: No. Although the patent supports Moderna’s COVID-19 vaccine, the claims broadly cover LNPs usable for any mRNA therapeutic or vaccine application.
Q4: What are the key components of the claimed lipid compositions?
A: Ionizable lipids with specific chemical features, structural lipids like DSPC, cholesterol, and PEG-lipids, with defined molar ratios for optimal performance.
Q5: When are key patent expirations expected, and what does this mean for the market?
A: Most related patents filed around 2017–2018 are expected to expire circa 2037–2038, opening opportunities for biosimilar development or proprietary innovation to fill the gap.
References
[1] United States Patent Office. USPTO Patent Serial No. 11,268,128.
[2] ModernaTX, Inc. Patent portfolio filings and public disclosures.
[3] Scientific literature on mRNA-LNP formulations and lipid chemistry.
[4] Patent landscape reports from IP analytics providers (e.g., PatentScope, Lens).
More… ↓
⤷ Start Trial
|
